Z. Butt
Jul 4, 2022
Citations
0
Influential Citations
0
Citations
Journal
The American Journal of Drug and Alcohol Abuse
Abstract
Elbasvir (EBR)/grazoprevir (GZR) is a direct acting antiviral used for the treatment of hepatitis C virus (HCV) genotypes (GT) 1 and 4 infection in adults (1,2). Several clinical studies, including trials of EBR/ GZR, have reported a high rate of sustained virologic response (SVR) in a variety of populations with HCV infection, most notably people with compensated cirrhosis, chronic kidney disease (CKD), and HCV/HIV coinfection (3–6). In this regard, people who inject drugs (PWIDs) are a high risk population for HCV infection that could benefit substantially from direct acting antiviral therapy, particularly elbasvir/ grazoprevir.